Literature DB >> 25806163

Biomarkers in the selection of maintenance therapy in non-small cell lung cancer.

Nichole T Tanner1, Carol A Sherman1, Gerard A Silvestri1.   

Abstract

Entities:  

Year:  2012        PMID： 25806163      PMCID： PMC4367572          DOI： 10.3978/j.issn.2218-6751.2012.03.02

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


× No keyword cloud information.
  9 in total

1.  Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Authors:  Rafael Rosell; Enric Carcereny; Radj Gervais; Alain Vergnenegre; Bartomeu Massuti; Enriqueta Felip; Ramon Palmero; Ramon Garcia-Gomez; Cinta Pallares; Jose Miguel Sanchez; Rut Porta; Manuel Cobo; Pilar Garrido; Flavia Longo; Teresa Moran; Amelia Insa; Filippo De Marinis; Romain Corre; Isabel Bover; Alfonso Illiano; Eric Dansin; Javier de Castro; Michele Milella; Noemi Reguart; Giuseppe Altavilla; Ulpiano Jimenez; Mariano Provencio; Miguel Angel Moreno; Josefa Terrasa; Jose Muñoz-Langa; Javier Valdivia; Dolores Isla; Manuel Domine; Olivier Molinier; Julien Mazieres; Nathalie Baize; Rosario Garcia-Campelo; Gilles Robinet; Delvys Rodriguez-Abreu; Guillermo Lopez-Vivanco; Vittorio Gebbia; Lioba Ferrera-Delgado; Pierre Bombaron; Reyes Bernabe; Alessandra Bearz; Angel Artal; Enrico Cortesi; Christian Rolfo; Maria Sanchez-Ronco; Ana Drozdowskyj; Cristina Queralt; Itziar de Aguirre; Jose Luis Ramirez; Jose Javier Sanchez; Miguel Angel Molina; Miquel Taron; Luis Paz-Ares
Journal:  Lancet Oncol       Date:  2012-01-26       Impact factor: 41.316

2.  Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.

Authors:  Makoto Maemondo; Akira Inoue; Kunihiko Kobayashi; Shunichi Sugawara; Satoshi Oizumi; Hiroshi Isobe; Akihiko Gemma; Masao Harada; Hirohisa Yoshizawa; Ichiro Kinoshita; Yuka Fujita; Shoji Okinaga; Haruto Hirano; Kozo Yoshimori; Toshiyuki Harada; Takashi Ogura; Masahiro Ando; Hitoshi Miyazawa; Tomoaki Tanaka; Yasuo Saijo; Koichi Hagiwara; Satoshi Morita; Toshihiro Nukiwa
Journal:  N Engl J Med       Date:  2010-06-24       Impact factor: 91.245

3.  Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer.

Authors:  Wolfram Brugger; Nadja Triller; Maria Blasinska-Morawiec; Stefan Curescu; Raimundas Sakalauskas; Georgy Moiseevich Manikhas; Julien Mazieres; Renaud Whittom; Carol Ward; Karen Mayne; Kerstin Trunzer; Federico Cappuzzo
Journal:  J Clin Oncol       Date:  2011-10-03       Impact factor: 44.544

4.  Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.

Authors:  Tetsuya Mitsudomi; Satoshi Morita; Yasushi Yatabe; Shunichi Negoro; Isamu Okamoto; Junji Tsurutani; Takashi Seto; Miyako Satouchi; Hirohito Tada; Tomonori Hirashima; Kazuhiro Asami; Nobuyuki Katakami; Minoru Takada; Hiroshige Yoshioka; Kazuhiko Shibata; Shinzoh Kudoh; Eiji Shimizu; Hiroshi Saito; Shinichi Toyooka; Kazuhiko Nakagawa; Masahiro Fukuoka
Journal:  Lancet Oncol       Date:  2009-12-18       Impact factor: 41.316

5.  Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.

Authors:  Federico Cappuzzo; Tudor Ciuleanu; Lilia Stelmakh; Saulius Cicenas; Aleksandra Szczésna; Erzsébet Juhász; Emilio Esteban; Olivier Molinier; Wolfram Brugger; Ivan Melezínek; Gaëlle Klingelschmitt; Barbara Klughammer; Giuseppe Giaccone
Journal:  Lancet Oncol       Date:  2010-05-20       Impact factor: 41.316

6.  Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.

Authors:  Caicun Zhou; Yi-Long Wu; Gongyan Chen; Jifeng Feng; Xiao-Qing Liu; Changli Wang; Shucai Zhang; Jie Wang; Songwen Zhou; Shengxiang Ren; Shun Lu; Li Zhang; Chengping Hu; Chunhong Hu; Yi Luo; Lei Chen; Ming Ye; Jianan Huang; Xiuyi Zhi; Yiping Zhang; Qingyu Xiu; Jun Ma; Li Zhang; Changxuan You
Journal:  Lancet Oncol       Date:  2011-07-23       Impact factor: 41.316

7.  Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer.

Authors:  Fred R Hirsch; Marileila Varella-Garcia; Paul A Bunn; Wilbur A Franklin; Rafal Dziadziuszko; Nick Thatcher; Alex Chang; Purvish Parikh; José Rodrigues Pereira; Tudor Ciuleanu; Joachim von Pawel; Claire Watkins; Angela Flannery; Gillian Ellison; Emma Donald; Lucy Knight; Dinah Parums; Nicholas Botwood; Brian Holloway
Journal:  J Clin Oncol       Date:  2006-11-01       Impact factor: 44.544

8.  Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.

Authors:  Tony S Mok; Yi-Long Wu; Sumitra Thongprasert; Chih-Hsin Yang; Da-Tong Chu; Nagahiro Saijo; Patrapim Sunpaweravong; Baohui Han; Benjamin Margono; Yukito Ichinose; Yutaka Nishiwaki; Yuichiro Ohe; Jin-Ji Yang; Busyamas Chewaskulyong; Haiyi Jiang; Emma L Duffield; Claire L Watkins; Alison A Armour; Masahiro Fukuoka
Journal:  N Engl J Med       Date:  2009-08-19       Impact factor: 91.245

9.  Screening for epidermal growth factor receptor mutations in lung cancer.

Authors:  Rafael Rosell; Teresa Moran; Cristina Queralt; Rut Porta; Felipe Cardenal; Carlos Camps; Margarita Majem; Guillermo Lopez-Vivanco; Dolores Isla; Mariano Provencio; Amelia Insa; Bartomeu Massuti; Jose Luis Gonzalez-Larriba; Luis Paz-Ares; Isabel Bover; Rosario Garcia-Campelo; Miguel Angel Moreno; Silvia Catot; Christian Rolfo; Noemi Reguart; Ramon Palmero; José Miguel Sánchez; Roman Bastus; Clara Mayo; Jordi Bertran-Alamillo; Miguel Angel Molina; Jose Javier Sanchez; Miquel Taron
Journal:  N Engl J Med       Date:  2009-08-19       Impact factor: 91.245
  9 in total
  5 in total

1.  PEBP4 enhanced HCC827 cell proliferation and invasion ability and inhibited apoptosis.

Authors:  Guiping Yu; Zhenya Shen; Guoqiang Chen; Xiaomei Teng; Yanqiu Hu; Bin Huang
Journal:  Tumour Biol       Date:  2012-09-15

2.  Lymphocyte to monocyte ratio is associated with response to first-line platinum-based chemotherapy and prognosis of early-stage non-small cell lung cancer patients.

Authors:  Ying-Jian Song; Li-Xin Wang; Yong-Qing Hong; Zheng-Hong Lu; Qiang Tong; Xiao-Zheng Fang; Juan Tan
Journal:  Tumour Biol       Date:  2015-11-11

3.  Prognostic value of a novel scoring system using inflammatory response biomarkers in non-small cell lung cancer: A retrospective study.

Authors:  Yan Wang; Xu Hu; Wenying Xu; Haoyuan Wang; Yu Huang; Guowei Che
Journal:  Thorac Cancer       Date:  2019-05-18       Impact factor: 3.500

Review 4.  Prognostic value of the neutrophil to lymphocyte ratio in lung cancer: A meta-analysis.

Authors:  Yongmei Yin; Jun Wang; Xuedong Wang; Lan Gu; Hao Pei; Shougang Kuai; Yingying Zhang; Zhongbo Shang
Journal:  Clinics (Sao Paulo)       Date:  2015-07-01       Impact factor: 2.365

5.  Direct bilirubin levels are prognostic in non-small cell lung cancer.

Authors:  Ying-Jian Song; Xin-Huai Gao; Yong-Qing Hong; Li-Xin Wang
Journal:  Oncotarget       Date:  2017-12-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.